Country: Canada
Language: English
Source: Health Canada
PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM)
FRESENIUS KABI CANADA LTD
J01CR05
PIPERACILLIN AND BETA-LACTAMASE INHIBITOR
36G; 4.5G
POWDER FOR SOLUTION
PIPERACILLIN (PIPERACILLIN SODIUM) 36G; TAZOBACTAM (TAZOBACTAM SODIUM) 4.5G
INTRAVENOUS
15G/50G
Prescription
EXTENDED-SPECTRUM PENICILLINS
Active ingredient group (AIG) number: 0225919008; AHFS:
APPROVED
2017-07-07
_ _ _Piperacillin and Tazobactam for Injection _ _Page 1 of 43_ PRODUCT MONOGRAPH INCUDING PATIENT MEDICATION INFORMATION PR PIPERACILLIN AND TAZOBACTAM FOR INJECTION Piperacillin Sodium/Tazobactam Sodium Lyophilized Powder for Injection For Intravenous Use Only MANUFACTURER’S STANDARD PIPERACILLIN 12 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 1.5 G (AS TAZOBACTAM SODIUM) PER VIAL PIPERACILLIN 36 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 4.5 G (AS TAZOBACTAM SODIUM) PER VIAL Antibiotic/β-lactamase Inhibitor FRESENIUS KABI CANADA LTD. 165 Galaxy Blvd, Suite 100 Toronto, Ontario M9W 0C8 Date of Revision: November 18, 2020 Submission Control No.: 246054 _ _ _Piperacillin and Tazobactam for Injection _ _Page 2 of 43_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................5 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................12 DOSAGE AND ADMINISTRATION ..............................................................................14 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY ..........................................................................................21 SPECIAL HANDLING INSTRUCTIONS ...................................................... Read the complete document